Publications [#273559] of Richard S. Keefe

Journal Articles

1. Keefe, RSE; Seidman, LJ; Christensen, BK; Hamer, RM; Sharma, T; Sitskoorn, MM; Rock, SL; Woolson, S; Tohen, M; Tollefson, GD; Sanger, TM; Lieberman, JA; HGDH Research Group, (2006). Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis.. Biological Psychiatry, 59(2), 97-105. [16140282], [doi]
   (last updated on 2024/01/01)

   Abstract:
   BACKGROUND: Neurocognitive deficits are severe in first-episode psychosis. METHODS: Patients (N = 263) with first-episode psychosis (schizophrenia, schizoaffective, or schizophreniform disorders) were randomly assigned to double-blind treatment with olanzapine (mean 11.30 mg/day) or haloperidol (mean 4.87 mg/day) for 104 weeks. A neurocognitive battery was administered at baseline (n = 246) and 12 (n = 167), 24 (n = 126), 52 (n = 89), and 104 (n = 46) weeks during treatment. Weighted principal component and unweighted composite scores were derived from individual tests. RESULTS: Both treatment groups demonstrated significant improvement on both composite scores. On the basis of the weighted composite score, olanzapine had greater improvement than haloperidol only at 12 (p = .014) and 24 (p = .029) weeks. For the unweighted composite, olanzapine had significantly better improvement compared with haloperidol only at week 12 (p = .044). At week 12 only, olanzapine improved performance on the Digit Symbol and Continuous Performance Test significantly more than haloperidol. CONCLUSIONS: Both antipsychotic agents appeared to improve neurocognitive functioning among first-episode psychosis patients with schizophrenia. A significantly greater benefit in terms of neurocognitive improvement was found with olanzapine than with haloperidol at weeks 12 and 24.